Compare CDNA & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | INMD |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 879.2M |
| IPO Year | 2014 | 2019 |
| Metric | CDNA | INMD |
|---|---|---|
| Price | $20.42 | $13.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 6 |
| Target Price | ★ $26.67 | $16.75 |
| AVG Volume (30 Days) | ★ 723.7K | 698.9K |
| Earning Date | 02-25-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | 1.22 | ★ 2.21 |
| Revenue | $357,998,000.00 | ★ $364,494,000.00 |
| Revenue This Year | $14.47 | N/A |
| Revenue Next Year | $11.35 | $3.33 |
| P/E Ratio | $16.81 | ★ $6.31 |
| Revenue Growth | ★ 14.46 | N/A |
| 52 Week Low | $10.96 | $13.14 |
| 52 Week High | $25.55 | $19.78 |
| Indicator | CDNA | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 41.10 |
| Support Level | $19.48 | $13.73 |
| Resistance Level | $21.49 | $14.23 |
| Average True Range (ATR) | 1.18 | 0.42 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 76.57 | 9.27 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.